Azvudine reduces the mortality rate of patients with Coronavirus disease 2019: a single-center retrospective analysis study
Zhen Zhong, Xiao-Feng Liu, Xiao-Zhong Zhou, Jia-Ning Zhong, Li-Cheng Zhou, Rong Li, Xian-Fa Liu
doi:10.21203/rs.3.rs-4157424/v1
Background: Several therapeutic drugs have been authorized for the treatment of patients with Coronavirus disease 2019 (COVID-19). However, further research on the mechanisms of action, e cacy, and target populations of these novel therapeutic drugs are necessary. Hence, this study aimed to investigate the effectiveness of azvudine in hospitalized patients with COVID-19. Methods: We conducted a retrospective cohort study of patients with COVID-19 admitted to our hospital from December 1, 2022, to March 31, 2023. Patients were divided into retrospective cohorts receiving azvudine antiviral therapy and standard treatment, and were followed-up for up to 28 days. Results: Prior to data processing, azvudine treatment was associated with reduced mortality rates at 7 days (1.09/1000 persons vs.5.06/1000 persons, p<0.001)and 14 days (3.35/1000 persons vs. 5.65/1000 persons, p=0.001). After propensity score matching, a decrease in mortality rates at 7 days (0.08/1000 persons vs.6.29/1000 persons, p<0.001), 14 days (3.42/1000 persons vs. 7.26/1000 persons, p<0.001), and 28 days (4.33/1000 persons vs. 7.29/1000 persons, p=0.003) were observed following azvudine treatment. After inverse probability of treatment weighting adjustment, the results were consistent with propensity score matching. In the clinical subgroup analysis, for hospitalized severe and critical patients with COVID-19, azvudine treatment intervention signi cantly reduced patient mortality rates. Conclusions: The study suggests that in hospitalized patients with COVID-19, azvudine treatment signi cantly reduces patient mortality rates in hospitalized COVID-19 infections, wherein the effects are more pronounced in severe and critical patients.
Declarations Ethics approval and consent to participate was no direct involvement in the conception, design, or implementation of this study. The requirement for patient consent was waived for this retrospective study, which utilized data from electronic medical records. This study was approved by the Ethics Committee of the First A liated Hospital of the Gannan Medical University Hospital (LLSL-2024065).
Consent for publication Not applicable.
Competing interests The authors declare that they have no competing interests.
Author Contributions Statement XianfaL JZ designed the experiments. XiaoL was responsible for clinical assessment of patients. LZ, XZ, LR,and ZZ collected the data. JZ was responsible for data management. JZ and ZZ conducted the statistical analysis. This article was written by ZZ, and reviewed by XianfaL. All the authors have reviewed and approved of the nal manuscript.
Supplementary Files This is a list of supplementary les associated with this preprint. Click to download. azvudineattachment.docx
References
Bertuccio, The impact of early therapies for COVID-19 on death, hospitalization and persisting symptoms: a retrospective study, Infection,
doi:10.1007/s15010-023-02028-5Deng, Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, Journal of medical virology,
doi:10.1002/jmv.28756Deng, Real-world effectiveness of Azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19: A retrospective cohort study, Journal of medical virology,
doi:10.1002/jmv.28756Gao, Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19, The Journal of infection,
doi:10.1016/j.jinf.2023.03.023Gentile, Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study, Vaccines,
doi:10.3390/vaccines10101731Gentile, Scotto, Schiano Moriello, Pinchera, Villari et al., Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a reallife study, Vaccines,
doi:10.3390/vaccines10101731Lui, Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong, JAMA network open,
doi:10.1001/jamanetworkopen.2023.14393Morris, Lee, Nirmatrelvir for Nonhospitalized Adults with Covid-19, The New England journal of medicine,
doi:10.1056/NEJMc2206277Shen, Xiao, Sun, Li, Wu et al., Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study, medRxiv,
doi:10.1101/2023.01.23.23284899Wang, Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world study, EClinicalMedicine,
doi:10.1016/j.eclinm.2024.102468Wong, Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with con rmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet,
doi:10.1016/S0140-6736(22)01586-0Zhang, Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal transduction and targeted therapy,
doi:10.1038/s41392-021-00835-6Zhou, Azvudine and nirmatrelvir-ritonavir in hospitalized patients with moderate-tosevere COVID-19: Emulation of a randomized target trial, Journal of medical virology,
doi:10.1002/jmv.29318
